thepeoplesvoice.tv

Biden’s FDA has authorized the use of a new and experimental Covid vaccine from Novamax under emergency use authorization, despite the fact that it hasn’t been tested on humans and does not have a licence.

The Novavax Covid jab uses experimental vaccine technology that is said to be even more radical than mRNA.

“The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted,” the Novavax website said. “The EUA of this product is in duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated, or the authorization is revoked sooner.”

Infowars.com reports: Interestingly, President Joe Biden ended the Covid emergency over a year ago, bringing into question the authenticity of the Covid pandemic ’emergency’ authorization.

Novavax’s Covid vaccine has been available for patients in a number of countries outside the U.S. for a number of years now. It is being billed to Americans as an alternative for those hesitant of taking the exotic modified mRNA novel technology into their bodies.

Despite the Novavax shot being of a more traditional vaccine technology, the listed side effects on the manufacture’s website read similar to what has become synonymous with the mRNA shots, including myocarditis, pericarditis and other ‘serious and unexpected’ side effects.

While the original Novavax Covid vaccines were analyzed in clinical trials, the FDA authorized the use of the new Novavax Covid vaccine (for more current Covid variants) under EUA without clinical trials being done on the updated version.

“The FDA evaluated manufacturing data to support the change to the 2023-2024 formula of the Novavax COVID-19 Vaccine, Adjuvanted. Additionally, the FDA evaluated non-clinical immune response data suggesting that the vaccine provides protection against the currently circulating COVID-19 variants. The agency also relied on its evaluation of safety and effectiveness data from clinical trials of Novavax COVID-19, Vaccine, Adjuvanted (Original monovalent) and investigational monovalent and bivalent Novavax COVID-19 adjuvanted vaccines, as well as postmarketing data. The data accrued with these Novavax COVID-19 vaccines are relevant to Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) as the vaccines are manufactured using a similar process,” an FDA press release said on October 3, 2023.